| Absalom H Tilley, MD | |
|
1003 Schneider Dr, Malvern, AR 72104-4811 | |
| (501) 337-5678 | |
| (501) 332-6759 |
| Full Name | Absalom H Tilley |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 35 Years |
| Location | 1003 Schneider Dr, Malvern, Arkansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275558918 | NPI | - | NPPES |
| 117040001 | Medicaid | AR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 36912 (Oklahoma) | Secondary |
| 207R00000X | Internal Medicine | DR.00655596 (Colorado) | Secondary |
| 207R00000X | Internal Medicine | C7758 (Arkansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baptist Health Medical Center-hot Springs County | Malvern, AR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Healthy Connections, Inc. | 9931018421 | 15 |
News Archive
Compared with routine care, weight loss surgery was linked with a reduced risk of hypertension, heart failure, and early death in a study based on information from a primary care database in the UK.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ:APCVZ) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Deferoxamine Mesylate for Injection, USP, in two dosage strengths. Deferoxamine Mesylate is therapeutically equivalent to the reference-listed drug Desferal®, which is marketed by the innovator Novartis.
Researchers have a new understanding of the process cells use to ensure that sperm and eggs begin life with exactly one copy of each chromosome - a process that must be exquisitely regulated to prevent problems such as miscarriages and mental retardation.
A team of researchers measured the infectivity of SARS-CoV-2 variants C.1.2, Mu, and Delta+501S spike proteins and determined the susceptibility to neutralizing antibodies.
The peer reviewed guidelines will be available in the September 2010 issue, (Volume 53, No.3) of the Journal of Hepatology and online in advance of publication at http://www.ncbi.nlm.nih.gov/pubmed/20633946 . They also provide recommendations for the management of spontaneous bacterial peritonitis and hepatorenal syndrome, which often affect patients with cirrhosis.
› Verified 6 days ago
| Entity Name | Glutality Provider Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083256168 PECOS PAC ID: 9032549837 Enrollment ID: O20201125000977 |
News Archive
Compared with routine care, weight loss surgery was linked with a reduced risk of hypertension, heart failure, and early death in a study based on information from a primary care database in the UK.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ:APCVZ) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Deferoxamine Mesylate for Injection, USP, in two dosage strengths. Deferoxamine Mesylate is therapeutically equivalent to the reference-listed drug Desferal®, which is marketed by the innovator Novartis.
Researchers have a new understanding of the process cells use to ensure that sperm and eggs begin life with exactly one copy of each chromosome - a process that must be exquisitely regulated to prevent problems such as miscarriages and mental retardation.
A team of researchers measured the infectivity of SARS-CoV-2 variants C.1.2, Mu, and Delta+501S spike proteins and determined the susceptibility to neutralizing antibodies.
The peer reviewed guidelines will be available in the September 2010 issue, (Volume 53, No.3) of the Journal of Hepatology and online in advance of publication at http://www.ncbi.nlm.nih.gov/pubmed/20633946 . They also provide recommendations for the management of spontaneous bacterial peritonitis and hepatorenal syndrome, which often affect patients with cirrhosis.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Absalom H Tilley, MD 1003 Schneider Dr, Malvern, AR 72104-4811 Ph: (479) 437-3449 | Absalom H Tilley, MD 1003 Schneider Dr, Malvern, AR 72104-4811 Ph: (501) 337-5678 |
News Archive
Compared with routine care, weight loss surgery was linked with a reduced risk of hypertension, heart failure, and early death in a study based on information from a primary care database in the UK.
APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ:APCVZ) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Deferoxamine Mesylate for Injection, USP, in two dosage strengths. Deferoxamine Mesylate is therapeutically equivalent to the reference-listed drug Desferal®, which is marketed by the innovator Novartis.
Researchers have a new understanding of the process cells use to ensure that sperm and eggs begin life with exactly one copy of each chromosome - a process that must be exquisitely regulated to prevent problems such as miscarriages and mental retardation.
A team of researchers measured the infectivity of SARS-CoV-2 variants C.1.2, Mu, and Delta+501S spike proteins and determined the susceptibility to neutralizing antibodies.
The peer reviewed guidelines will be available in the September 2010 issue, (Volume 53, No.3) of the Journal of Hepatology and online in advance of publication at http://www.ncbi.nlm.nih.gov/pubmed/20633946 . They also provide recommendations for the management of spontaneous bacterial peritonitis and hepatorenal syndrome, which often affect patients with cirrhosis.
› Verified 6 days ago
Jeffery Mack, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1001 Schneider Dr, Malvern, AR 72104 Phone: 501-851-7402 Fax: 501-851-4753 | |
Dr. Altimus Ray Bollen, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1002 Schneider Dr, Suite 104, Malvern, AR 72104 Phone: 501-337-9066 Fax: 501-332-5265 | |
Dr. Bruce Kent Burton, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2223 Grant St, Malvern, AR 72104 Phone: 501-337-9031 Fax: 501-337-9033 |